A year of maiden profitability
​Venture Life (VLG) combines innovation, product development, formulation and contract manufacturing expertise and an international partner distribution network across over 40 countries. VLG's product range spans brands that address common ailments associated with the ageing process.
Pre-close 2016 update:on track to report £14.3m of total group revenues at FY16 results, equivalent to 57% year-on-year growth, consequently hitting the target of a maiden positive EBITDA result with an end of year gross cash position of c £2m.
Key growth drivers were expansion of the brands business direct in the UK and through formation of global distribution agreements, and continued investment in its development and manufacturing business which increases its flexibility to roll-out new products.
The year has started well, with the growing order book in place and January revenues 45% above the same period in 2016. Looking forward, drivers include further launches. VLG unveils today 3 products developed in-house, to be launched by international partners in 2017.
VLG shares trade well below their 12-month high of 78p, on an EV/2016 sales multiple of c 1.5x, while our DCF valuation supports a fair value of 120 pence per share.
Venture Life Group is a holding company, engaged in the development and commercialisation of healthcare products. Co.'s products address healthcare issues from oral healthcare, women's intimate health, neurology, cardiovascular and dermatology. Co.'s products include UltraDEX, a product range for the treatment of halitosis. Co.'s other brands are: NeuroAge™, a food supplement indicated for short-term memory loss and cognitive function; Myco Clear™ , indicated for the management of onychomycosis; Rosa calma™, a range of three topical products that treats this inflammatory skin condition; and Procto-eze™ Plus, a range of medical devices and cosmetics for the treatment of haemorrhoids.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.